SARASOTA, Fla., June 22, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTCBB:DNAG) President and Chief Executive Officer Richard Gabriel told shareholders at the Annual Meeting today that the ...

DNAPrint genomics Inc. is causing a stir in the scientific world. In a series of letters to the editor in "Nature Genetics," a worldwide scientific journal, DNAPrint's technologies are being debated.

DNAPrint Genomics Inc. Annual stock financials by MarketWatch. View the latest DNAG financial statements, income statements and financial ratios.

The German partner of DNAPrint Genomics Inc. has the go-ahead to begin its first human study of a drug intended to prevent migraine headaches. Biofrontera AG, in which DNAPrint owns a nearly 10 ...

SARASOTA -- A genetics test owned by DNAPrint Genomics Inc. helped lead investigators to a suspect in a string of Louisiana murders. Authorities arrested Derrick T. Lee in Atlanta last week in ...

SARASOTA -- DNAPrint Genomics posted a loss of $906,292 during the first quarter as it continued efforts to milk profits out of its genetic testing products. The per-share measure of the loss is so ...

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Ellipsis Biotherapeutics Corporation, its wholly owned subsidiary, has successfully launched several new services in the areas of whole ...

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that representatives of Ellipsis Biotherapeutics Corporation, a wholly owned subsidiary of DNAPrint Genomics, will exhibit at the American Society ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...